Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$47.79 USD
-1.21 (-2.47%)
Updated Nov 25, 2024 04:00 PM ET
After-Market: $47.78 -0.01 (-0.02%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
HALO 47.79 -1.21(-2.47%)
Will HALO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HALO
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Other News for HALO
Strategic Focus and ENHANZE Platform Drive Buy Rating for Halozyme
Halozyme: Growth Amid Uncertainty After Failed Acquisition (Rating Downgrade)
Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
Evotec takes notice of Halozyme withdrawal, convicted in standalone strategy